Vertex Pharmaceuticals Incorporated Earnings Preview: Can This Streak Finally End?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) will report earnings after markets close on Tuesday, April 30th. Vertex Pharmaceuticals Incorporated discovers, develops, and commercializes novel, small molecule pharmaceuticals for the treatment of diseases for which there are currently limited or no effective treatments. The Company is developing drugs for the treatment of viral diseases, multidrug resistance in cancer, inflammatory and autoimmune diseases, and neurodegenerative diseases.
Here is your Cheat Sheet to Vertex Pharmaceuticals Incorporated Earnings:
Earnings Expectations: Analysts expect earnings of $-0.19 per share on revenues of $307.66 million.
Analysts have a more negative outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings has fallen from a loss of $0.16 to a loss $0.22. For the current year, the average estimate is a loss of $0.97, which is worse than the estimate ninety days ago.
Here’s how Vertex Pharmaceuticals Incorporated has been performing on an annual basis:
|Revenue ($) in millions||175.50||101.89||143.37||1,411||1,527|
|Diluted EPS ($)||-3.27||-3.71||-3.77||0.14||-0.50|
Next, our CHEAT SHEET investing framework asks us to drill down to the recent quarterly data:
|Quarter||Dec. 31, 2011||Mar. 31, 2012||Jun. 30, 2012||Sep. 30, 2012||Dec. 31, 2012|
|Revenue ($) in millions||563.34||438.74||418.30||336.01||333.99|
|Diluted EPS ($)||0.7131||0.43||-0.31||-0.27||-0.3548|
Vertex Pharmaceuticals Incorporated has missed analyst estimates 4 times in the past four quarters. Shareholders could expect a bust if the company misses estimates.